CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc., a privately-held oncology and autoimmune disease drug development company, today announced that the FDA has granted Orphan Drug Designation to fludarabine phosphate oral tablets for the treatment of B-cell chronic lymphocytic leukemia. Xanthus licensed the exclusive right to develop and commercialize oral fludarabine in the United States from Schering AG (now Bayer Schering Pharma AG) in October 2006.
